Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00

Arcturus Therapeutics (NASDAQ:ARCT) had its price objective reduced by Piper Sandler from $72.00 to $25.00 in a research report report published on Wednesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on ARCT. HC Wainwright lowered their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Roth Mkm began coverage on Arcturus Therapeutics in a research note on Thursday, January 22nd. They set a “buy” rating and a $20.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, January 21st. Citigroup lowered their price objective on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $30.33.

Arcturus Therapeutics Trading Down 1.9%

Shares of ARCT opened at $7.11 on Wednesday. The firm has a fifty day simple moving average of $7.32 and a two-hundred day simple moving average of $11.25. The firm has a market cap of $202.07 million, a PE ratio of -2.99 and a beta of 2.40. Arcturus Therapeutics has a 1-year low of $5.85 and a 1-year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.11). Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%.The firm had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $14.32 million. As a group, research analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC increased its position in Arcturus Therapeutics by 39.4% in the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock worth $16,006,000 after buying an additional 738,378 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Arcturus Therapeutics by 4.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,026,588 shares of the biotechnology company’s stock worth $12,423,000 after buying an additional 78,753 shares during the period. Amova Asset Management Americas Inc. lifted its position in shares of Arcturus Therapeutics by 4.0% during the 4th quarter. Amova Asset Management Americas Inc. now owns 2,026,588 shares of the biotechnology company’s stock valued at $12,403,000 after buying an additional 78,753 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Arcturus Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock valued at $34,752,000 after buying an additional 75,440 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Arcturus Therapeutics by 112.0% during the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after acquiring an additional 327,626 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics News Roundup

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Company will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 11), giving management a near?term opportunity to provide program updates and financing/cost?pathway clarity that could stabilize sentiment. Arcturus Therapeutics to Attend Upcoming Investor Conference
• Neutral Sentiment: Citigroup cut its price target from $66 to $21 but maintained a “buy” rating — this reduces a high upside anchor and likely tempers conviction among momentum buyers, though the maintained buy stance leaves room for positive reaction if management news is constructive. Citi price target cut coverage
• Neutral Sentiment: Short?interest data published for early March appears to be erroneous (shows 0 shares / NaN changes); investors should treat those metrics with caution until corrected — unreliable short data reduces clarity on potential short?squeeze dynamics. (Source: market data entries)
• Negative Sentiment: HC Wainwright materially lowered EPS forecasts across 2026–2030 (e.g., FY2026 cut to ($3.07) from ($2.19); FY2029 and FY2030 swung to large expected losses), and reduced quarterly EPS estimates for Q1–Q4 2026 — this increases downside pressure by signaling a longer path to profitability and higher cash burn assumptions. HC Wainwright estimate revisions (market summary)
• Negative Sentiment: Recent Q4 earnings commentary and third?party assessments highlighted missed revenue and EPS vs. expectations, reinforcing short?term weakness and investor skepticism until clinical/program milestones or clearer financing plans are provided. Arcturus Therapeutics Q4 2025 Earnings Call Summary Q4 earnings assessment

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.